A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration

Chair: Michael Roden (DEU)

17:45 – 17:55	Introduction. The Growing Burden of MASLD/MASH: A Call to Action	Michael Roden (DEU)
17:55 – 18:10	Need to Improve Screening and Diagnosis in Patients with Diabetes	Michael Trauner (AUT)
18:10 – 18:25	Changing the MASH Paradigm with THR-β Agonists and Other Disease-specific Therapies	Amalia Gastaldelli (ITA)
18:25 – 18:35	Integrating MASLD/MASH-Specific Therapy into Guideline-Aligned Real-World Practice	All faculty
18:35 – 18:45	Conclusions and Q&A	All faculty

AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Supported by an educational grant from Madrigal Pharmaceuticals